Today's Daily Dose brings you news about Anavex's encouraging results from its Alzheimer's study; Esperion's promising phase III clinical development program evaluating the LDL-C-lowering efficacy of bempedoic acid; Grifol's AMBAR trial; Retrophin's long-term data from DUET study, and Ultagenyx's failed glucose transporter type-1 deficiency syndrome (Glut1 DS) trial.
from RTT - Biotech https://ift.tt/2CPMh9U
via IFTTT
No comments:
Post a Comment